Fage Clément, Hénaut Mathilde, Carbonneau Julie, Piret Jocelyne, Boivin Guy
Research Center of the CHU de Québec, Department of Microbiology-Immunology and Infectious Diseases, Faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada.
Viruses. 2022 Feb 15;14(2):395. doi: 10.3390/v14020395.
The types of interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses are not well-characterized due to the low number of co-infection cases described since the onset of the pandemic. We have evaluated the interactions between SARS-CoV-2 (D614G mutant) and influenza A(H1N1)pdm09 or respiratory syncytial virus (RSV) in the nasal human airway epithelium (HAE) infected simultaneously or sequentially (24 h apart) with virus combinations. The replication kinetics of each virus were determined by RT-qPCR at different post-infection times. Our results showed that during simultaneous infection, SARS-CoV-2 interferes with RSV-A2 but not with A(H1N1)pdm09 replication. The prior infection of nasal HAE with SARS-CoV-2 reduces the replication kinetics of both respiratory viruses. SARS-CoV-2 replication is decreased by a prior infection with A(H1N1)pdm09 but not with RSV-A2. The pretreatment of nasal HAE with BX795, a TANK-binding kinase 1 inhibitor, partially alleviates the reduced replication of SARS-CoV-2 or influenza A(H1N1)pdm09 during sequential infection with both virus combinations. Thus, a prior infection of nasal HAE with SARS-CoV-2 interferes with the replication kinetics of A(H1N1)pdm09 and RSV-A2, whereas only A(H1N1)pdm09 reduces the subsequent infection with SARS-CoV-2. The mechanism involved in the viral interference between SARS-CoV-2 and A(H1N1)pdm09 is mediated by the production of interferon.
自新冠疫情爆发以来,由于共感染病例数量较少,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与其他呼吸道病毒之间的相互作用类型尚未得到充分表征。我们评估了SARS-CoV-2(D614G突变体)与甲型流感病毒(H1N1)pdm09或呼吸道合胞病毒(RSV)在人鼻气道上皮细胞(HAE)中同时或先后(间隔24小时)感染病毒组合时的相互作用。通过RT-qPCR在不同感染后时间测定每种病毒的复制动力学。我们的结果表明,在同时感染期间,SARS-CoV-2会干扰RSV-A2的复制,但不会干扰甲型流感病毒(H1N1)pdm09的复制。鼻HAE预先感染SARS-CoV-2会降低两种呼吸道病毒的复制动力学。预先感染甲型流感病毒(H1N1)pdm09会降低SARS-CoV-2的复制,但预先感染RSV-A2则不会。用TANK结合激酶1抑制剂BX795预处理鼻HAE可部分缓解在两种病毒组合先后感染期间SARS-CoV-2或甲型流感病毒(H1N1)pdm09复制减少的情况。因此,鼻HAE预先感染SARS-CoV-2会干扰甲型流感病毒(H1N1)pdm09和RSV-A2的复制动力学,而只有甲型流感病毒(H1N1)pdm09会降低随后SARS-CoV-2的感染。SARS-CoV-2与甲型流感病毒(H1N1)pdm09之间病毒干扰所涉及的机制是由干扰素的产生介导的。